This study is designed to evaluate the combination of pembrolizumab and cabozantinib in subjects with locally advanced, recurrent, or metastatic renal cell carcinoma that has progressed after treatment with at least one prior VEGF-targeted therapy, or for whom VEGF-targeted therapy has proven to be intolerable, or is considered inappropriate.